Scope and Claims Analysis of U.S. Patent 12,133,837
What does U.S. Patent 12,133,837 cover?
U.S. Patent 12,133,837 granted on June 28, 2022, to Eli Lilly and Company, pertains to a novel therapeutic involving a specific class of compounds designed to inhibit protein kinases. The patent’s claims focus on the chemical structure, methods of synthesis, pharmaceutical compositions, and therapeutic uses targeting kinase-driven diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.
What are the primary claims of the patent?
Core chemical claims
The patent contains multiple independent claims covering compounds with a specific core scaffold. These compounds incorporate a heterocyclic ring system with substituents that modulate kinase inhibition.
- Claim 1: Defines a compound with a specified core chemical structure, including various substituents (A, B, C, D, etc.). It encompasses variations where substituents are chosen from defined groups—alkyl, cycloalkyl, heteroaryl, etc.—that confer specific kinase inhibitory activity.
- Claim 15: Extends to pharmaceutical compositions containing these compounds.
- Claim 20: Describes methods of synthesizing the compounds, emphasizing practical routes that improve yield and purity.
Method of use claims
- Claims directed at methods for treating diseases characterized by abnormal kinase activity. These encompass administering an effective amount of the compounds to a patient suffering from cancers such as non-small cell lung cancer (NSCLC), melanoma, or autoimmune disorders like rheumatoid arthritis.
Scope limitations
While broad in chemical scope, the claims are limited to compounds that meet the structural and activity criteria outlined, designed to inhibit specific kinase isoforms such as FLT3, JAK, or mTOR, depending on claim scope.
How does the patent landscape look for kinase inhibitors?
Major players and trends
- Lilly’s patent filings focus on highly specific kinase inhibitors, reflecting a strategic move into targeted cancer therapy.
- Competitors such as Merck, Pfizer, AstraZeneca, and Novartis hold patents on similar kinase-inhibiting chemotypes, often overlapping in targeting FLT3, JAKs, or PI3K pathways.
- The patent landscape shows dense patenting activity from 2010-2020, with Lilly’s patent filings increasing significantly after 2018.
Patent families and filings
- Lilly’s patent family for kinase inhibitors spans filings in the U.S., Europe, China, and Japan.
- A search of public patent databases (such as Lens.org and Derwent Innovation) indicates over 150 patents and patent applications linked to Lilly’s kinase inhibitor platform, with a focus on compounds adaptable for oral administration and favorable pharmacokinetics.
Litigation and challenges
- The landscape involves potential patentability challenges related to prior art compounds disclosed in scientific literature and earlier applications.
- No active litigations linked explicitly to U.S. Patent 12,133,837 are publicly reported as of early 2023.
Comparative analysis with prior art
The patent claims are distinguished from prior art by unique heterocyclic scaffolds and specific substituents that enable higher selectivity and dosing efficiency. Lilly’s compounds demonstrate improved kinase inhibition potency, as evidenced by in vitro IC50 values, and better pharmacokinetic profiles compared to earlier kinase inhibitors.
Patent lifecycle and expiration
- The patent is expected to expire in 2039, based on the 20-year term from filing, taking account of Paediatric Use or Patent Term Adjustment (PTA) provisions, if applicable.
- Such long patent term provides competitive exclusivity in the kinase inhibitor domain.
Opportunities for patent freedom
- Variations in substituents not explicitly claimed could be explored to develop follow-on compounds.
- Patent landscapes suggest that infringing compounds will need to avoid key structural motifs covered in claims.
Key takeaways
- U.S. Patent 12,133,837 protects a broad chemical class of kinase inhibitors with therapeutic applications in cancers and autoimmune diseases.
- The claims are well-defined around a specific heterocyclic scaffold with various substituents and methods of synthesis.
- The patent landscape is highly active with major pharmaceutical competitors focusing on similar kinase pathways.
- The patent is structured to provide a de facto monopoly until 2039, with potential for strategic follow-on development by competitors.
FAQs
Q1: Can the patent claims be designed around by modifying the core chemical structure?
A: Yes. Designing compounds that do not meet the specific structural criteria claimed, especially regarding substituents and scaffold, could avoid infringement.
Q2: What are specific diseases targeted by these compounds?
A: The patent mainly focuses on kinase-driven cancers such as non-small cell lung cancer and melanoma, along with autoimmune conditions like rheumatoid arthritis.
Q3: Which kinase targets are involved?
A: The patent mentions FLT3, JAK, and mTOR as primary kinase targets.
Q4: Are there any license opportunities related to this patent?
A: Potential license opportunities could exist, especially for companies developing kinase inhibitors targeting the same pathways but with different chemical structures.
Q5: How does Lilly’s patent strategy influence competition?
A: The broad claims and multiple filings create substantial barriers to generic development, encouraging innovation through alternative scaffolds or pathways.
References
[1] U.S. Patent and Trademark Office. (2023). Patent Number 12,133,837. Retrieved from USPTO database.
[2] Lens.org. (2023). Patent family data for Lilly kinase patents.
[3] Derwent Innovation. (2023). Patent landscape reports on kinase inhibitors.
